This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
Data availability
The data supporting the findings of this study are available on request from the corresponding author. The study was approved by the scientific board of GEMFIN.
References
Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129:667–79.
Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood. 2010;115:778–82.
Hernandez-Boluda JC, Pastor-Galan I, Arellano-Rodrigo E, Raya JM, Perez-Encinas M, Ayala R, et al. Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis. Br J Haematol. 2022;199:529–38.
Mora B, Guglielmelli P, Kuykendall A, Rumi E, Maffioli M, Palandri F, et al. Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients. Leukemia. 2022;36:2453–60.
Elliott MA, Pardanani A, Lasho TL, Schwager SM, Tefferi A. Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked. Haematologica. 2010;95:1788–91.
Guglielmelli P, Gangat N, Coltro G, Lasho TL, Loscocco GG, Finke CM, et al. Mutations and thrombosis in essential thrombocythemia. Blood Cancer J. 2021;11:77.
Furuya C, Morishita S, Hashimoto Y, Inano T, Ochiai T, Shirane S, et al. Impact of non-driver gene mutations on thrombo-haemorrhagic events in ET patients. Br J Haematol. 2024;204:221–8.
Cerquozzi S, Barraco D, Lasho T, Finke C, Hanson CA, Ketterling RP, et al. Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. Blood Cancer J. 2017;7:662.
Segura-Diaz A, Stuckey R, Florido Y, Gonzalez-Martin JM, Lopez-Rodriguez JF, Sanchez-Sosa S, et al. Thrombotic Risk Detection in Patients with Polycythemia Vera: The Predictive Role of DNMT3A/TET2/ASXL1 Mutations. Cancers. 2020;12:934.
Pasquer H, Daltro de Oliveira R, Vasseur L, Soret-Dulphy J, Maslah N, Zhao LP, et al. Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification. Leukemia. 2024;38:326–39.
Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.
Tefferi A, Guglielmelli P, Lasho TL, Gangat N, Ketterling RP, Pardanani A, et al. MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis. J Clin Oncol. 2018;36:1769–70.
Finazzi MC, Carobbio A, Cervantes F, Isola IM, Vannucchi AM, Guglielmelli P, et al. CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis. Leukemia. 2015;29:1209–10.
Garrote M, Lopez-Guerra M, Garcia-Pagan JC, Arellano-Rodrigo E, Ferrer-Marin F, Hernandez-Boluda JC, et al. Genomic classification and outcomes of young patients with polycythemia vera and essential thrombocythemia according to the presence of splanchnic vein thrombosis and its chronology. Ann Hematol. 2024;103:737–47.
Guglielmelli P, Loscocco GG, Mannarelli C, Rossi E, Mannelli F, Ramundo F, et al. JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis. Blood Cancer J. 2021;11:199.
Acknowledgements
We thank María Pereira for her helpful aid with the figures of this article.
Funding
The Spanish Registry of Myelofibrosis was initially sponsored by a grant from Novartis Pharmaceuticals, Inc. This work was supported by the grants PI21/00538, PI21/00347 and PI21/00231 from the Instituto de Salud Carlos III, Spanish Ministry of Health.
Author information
Authors and Affiliations
Contributions
JCHB prepared the GEMFIN database; AP performed the statistical analysis; IPG, AP and JCHB wrote the paper; all co-authors critically evaluated the manuscript, made substantial recommendations, and approved the submission of this manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Pastor-Galán, I., Pereira, A., Arellano-Rodrigo, E. et al. Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis. Leukemia 38, 2483–2486 (2024). https://doi.org/10.1038/s41375-024-02389-2
Received:
Revised:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41375-024-02389-2
